Breaking News Instant updates and real-time market news.

NVO

Novo Nordisk

$50.70

-1.495 (-2.86%)

06:55
03/25/19
03/25
06:55
03/25/19
06:55

Novo Nordisk reports results of PIONEER 3 trial of oral semaglutide

Presented at the Endocrine Society Annual Meeting in New Orleans, Louisiana, with simultaneous publication in the Journal of the American Medical Association, PIONEER 3 was a phase 3a trial investigating the efficacy and long-term safety of oral semaglutide 3 mg, 7 mg and 14 mg compared with sitagliptin 100 mg in adults with type 2 diabetes inadequately controlled with metformin, with or without sulfonylurea, over 78 weeks. Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia, Novo Nordisk reports. Non-inferiority for oral semaglutide 3 mg for HbA1c reductions at 26 weeks was not confirmed. In PIONEER 3, the primary endpoints of HbA1c and confirmatory secondary endpoint of change in body weight were assessed after 26 weeks of treatment. When applying the primary statistical approach[a], oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c reductions of 1.0% and 1.3% at 26 weeks, compared to a 0.8% reduction with sitagliptin. Oral semaglutide 3 mg demonstrated a reduction in HbA1c of 0.6%; non-inferiority compared to sitagliptin was not confirmed. Furthermore, at 26 weeks, oral semaglutide 7 mg and 14 mg demonstrated superior body weight reductions of 2.2 kg and 3.1 kg, both compared to a 0.6 kg reduction for sitagliptin. When applying the secondary statistical approach[b] at week 26, oral semaglutide 7 mg and 14 mg demonstrated statistically significant reductions in HbA1c of 1.1% and 1.4%, respectively, compared to a 0.8% reduction with sitagliptin. Reductions in HbA1c seen with oral semaglutide 3 mg were 0.5% and compared to the reductions seen with sitagliptin, the difference is statistically significant in favor of sitagliptin. Reductions in body weight from baseline were statistically significant in favor of all three oral semaglutide doses. "Many people living with type 2 diabetes do not meet their blood glucose targets despite many available oral antidiabetic therapies," said Dr Dale Allison, PIONEER 3 investigator and director of medical research at the Hillcrest Family Health Center, Waco, Texas. "The PIONEER 3 findings are encouraging, as oral semaglutide demonstrated a clinically significant improvement in HbA1c and this investigational therapy has the potential to become the first oral GLP-1 receptor agonist for those living with type 2 diabetes."

  • 25

    Mar

NVO Novo Nordisk
$50.70

-1.495 (-2.86%)

01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche
JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm's European Analyst Focus List while removing Roche (RHHBY).
01/23/19
OTRG
01/23/19
NO CHANGE
OTRG
Novo Nordisk Ozempic script growth accelerates, says OTR Global
OTR Global's checks indicate Novo Nordisk's Ozempic script growth accelerated during Q4.
01/29/19
EXAN
01/29/19
INITIATION
EXAN
Outperform
Novo Nordisk reinstated with an Outperform at Exane BNP Paribas
02/01/19
MSCO
02/01/19
INITIATION
MSCO
Equal Weight
Novo Nordisk reinstated with an Equal Weight at Morgan Stanley

TODAY'S FREE FLY STORIES

OCFT

OneConnect

$0.00

(0.00%)

08:35
12/13/19
12/13
08:35
12/13/19
08:35
Syndicate
OneConnect 31.2M share IPO priced at $10.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ONCS

OncoSec

$2.39

-0.04 (-1.65%)

, MRK

Merck

$88.95

0.6 (0.68%)

08:34
12/13/19
12/13
08:34
12/13/19
08:34
Hot Stocks
OncoSec reports interim results from KEYNOTE-890 study »

OncoSec announced interim…

ONCS

OncoSec

$2.39

-0.04 (-1.65%)

MRK

Merck

$88.95

0.6 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

CFX

Colfax

$35.74

0.6 (1.71%)

08:34
12/13/19
12/13
08:34
12/13/19
08:34
Conference/Events
Colfax to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

08:33
12/13/19
12/13
08:33
12/13/19
08:33
Hot Stocks
Sarepta announces $250M of non-dilutive senior secured loan financing »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

08:33
12/13/19
12/13
08:33
12/13/19
08:33
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ATNX

Athenex

$16.94

-0.36 (-2.08%)

08:32
12/13/19
12/13
08:32
12/13/19
08:32
Hot Stocks
Athenex announces results from Phase III trial of oral paclitaxel »

Athenex announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PFE

Pfizer

$38.54

0.3 (0.78%)

08:32
12/13/19
12/13
08:32
12/13/19
08:32
Hot Stocks
Pfizer announces CHMP recommendation for approval of Vyndaqel »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TREE

LendingTree

$293.67

-13 (-4.24%)

08:31
12/13/19
12/13
08:31
12/13/19
08:31
Recommendations
LendingTree analyst commentary  »

LendingTree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$31.01

0.82 (2.72%)

08:30
12/13/19
12/13
08:30
12/13/19
08:30
Conference/Events
Unum Group to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

08:30
12/13/19
12/13
08:30
12/13/19
08:30
Options
One option delisting on December 13th »

Option delistings…

08:25
12/13/19
12/13
08:25
12/13/19
08:25
Conference/Events
Federal Reserve Bank of New York president participates in a discussion »

New York Federal Reserve…

FORM

FormFactor

$24.96

1.19 (5.01%)

, INTC

Intel

$57.56

0.52 (0.91%)

08:25
12/13/19
12/13
08:25
12/13/19
08:25
Recommendations
FormFactor, Intel, Samsung, TSMC analyst commentary  »

FormFactor price target…

FORM

FormFactor

$24.96

1.19 (5.01%)

INTC

Intel

$57.56

0.52 (0.91%)

SSNLF

Samsung

$0.00

(0.00%)

TSM

TSMC

$58.61

2.71 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 23

    Jan

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$47.44

1 (2.15%)

, FBHS

Fortune Brands

$65.51

0.31 (0.48%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Recommendations
Masco, Fortune Brands analyst commentary  »

Masco, Fortune Brands…

MAS

Masco

$47.44

1 (2.15%)

FBHS

Fortune Brands

$65.51

0.31 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$194.19

2.09 (1.09%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$88.89

0.9 (1.02%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$60.86

1.19 (1.99%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$32.84

0.58 (1.80%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Conference/Events
The FDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 08

    Mar

XLY

Consumer Discretionary Sector SPDR

$123.10

1.12 (0.92%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$60.92

0.85 (1.42%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$62.86

-0.32 (-0.51%)

08:22
12/13/19
12/13
08:22
12/13/19
08:22
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$62.54

-0.09 (-0.14%)

08:22
12/13/19
12/13
08:22
12/13/19
08:22
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$100.94

0.93 (0.93%)

08:22
12/13/19
12/13
08:22
12/13/19
08:22
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.